Skip to main content

4 Result(s)

within Caleb Bliss Remove this filter

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

The Impact of a Brief Motivational Intervention on Unprotected Sex and Sex While High Among Drug-Positive Emergency Department Patients Who Receive STI/HIV VC/T and Drug Treatment Referral as Standard of Care

Include preview-only content

  1. Article

    Open Access

    Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses

    Several recent phase 3 clinical trials of attention-deficit/hyperactivity disorder (ADHD) medications have used the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Here, we assess WFIRS-P res...

    David R. Coghill, Tamara Werner-Kiechle… in European Child & Adolescent Psychiatry (2021)

    Download PDF (1026 KB) View Article

  2. Article

    Open Access

    A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

    Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal surfa...

    Melissa Palmer, Lee Jennings, Debra G. Silberg… in BMC Pharmacology and Toxicology (2018)

    Download PDF (899 KB) View Article

  3. Article

    Open Access

    Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

    Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis. This phase 1, open-label study investigated the absorption...

    Nicholas Siebers, Melissa Palmer… in European Journal of Drug Metabolism and Ph… (2018)

    Download PDF (516 KB) View Article

  4. Article

    Open Access

    Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate

    SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European...

    David R. Coghill, Tobias Banaschewski, Caleb Bliss, Brigitte Robertson… in CNS Drugs (2018)

    Download PDF (768 KB) View Article